Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026

Spyre Therapeutics, Inc.

Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.
SPY001 enrollment complete ahead of schedule; SKYLINE Part A readouts now expected to begin Q2 2026.
Six total proof-of-concept readouts planned: 3 from SKYLINE (UC) and 3 from SKYWAY (RA, PsA, axSpA) by 4Q 2026.
Pro forma cash $783M as of Sept 30, 2025, including Oct 2025 offering net proceeds; runway into H2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.